Natural History of Sickle Cell Disease
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Apr 14, 2004
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Natural History of Sickle Cell Disease," is focused on understanding the experiences of individuals with sickle cell disease, particularly related to pain crises. It is important to note that this study is not testing new treatments; instead, it aims to gather information that could help improve care for those living with this condition. Participants will receive their regular medical care outside of the study and may have multiple visits at our clinic, where they might undergo additional tests as needed.
To be eligible for this trial, individuals must be 2 years or older and have known or suspected sickle cell disease. They should also be willing to provide consent, or have a parent or guardian provide consent for younger participants. If you or someone you know is interested, they will be seen at our sickle cell outpatient clinics at participating centers. This study is currently recruiting participants of all genders, and it provides an opportunity to contribute to valuable research that could benefit the sickle cell community in the future.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • Individuals with known or suspected sickle cell disease
- • 2 years of age and older
- • Willing to provide informed consent or appropriate informed consent from parent or legal guardian
- • Patients seen at sickle outpatient clinics at any one of the participating centers (CNHS or NIH).
- EXCLUSION CRITERIA:
- • Patient and/or guardian unable and unwilling to give informed consent or assent.
- • Patients less than 2 years of age.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Bethesda, Maryland, United States
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Swee Lay Thein, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials